Lilly press release on eloralintide FDA APPROVES GENERIC VERSION OF SAXENDA August 2025 In 2014, Saxenda (liraglutide) became the first GLP drug approved for weight loss
Gastrointestinal symptoms are the most common side effects, particularly nausea, vomiting, and diarrhea
Elderly patients may experience differential responses to GLP-1R agonists due to age-related changes in GLP1R expression, tumor microenvironment, and systemic physiology
The expressions of both shoot and root tissue of nine key genes, LsABCC3, LsCCD7, LsCCD8, LsD14, LsD27, LsHMA2, LsMAPK, LsMAX1, and LsMAX2 , in response to SL treatment under Pb stress were investigated using qRT-PCR
The journals Rapid Service Fee was funded by Alfasigma S.p.A
Moreover, the rise of outpatient and ambulatory care trends supports clinic growth as a preferred setting for ongoing weight loss management